Considerations for Size, Surface Charge, Polymer Degradation, Co‐Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases

Genito, Christopher J; Batty, Cole J.; Bachelder, Eric M.; Ainslie, Kristy M.

doi:10.1002/anbr.202000041

Cited by 47 publications

(40 citation statements)

References 166 publications

(241 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, translational materials must be easy and inexpensive to manufacture at scale to enable urgent responses to global demand 243 . At every stage of the design process, it is important to consider whether controlled delivery technology could be simplified without sacrificing efficacy and safety 218 , 244 .…”

Section: Discussionmentioning

confidence: 99%

Designing spatial and temporal control of vaccine responses

et al. 2021

View full text Add to dashboard Cite

Vaccines are the key technology to combat existing and emerging infectious diseases. However, increasing the potency, quality and durability of the vaccine response remains a challenge. As our knowledge of the immune system deepens, it becomes clear that vaccine components must be in the right place at the right time to orchestrate a potent and durable response. Material platforms, such as nanoparticles, hydrogels and microneedles, can be engineered to spatially and temporally control the interactions of vaccine components with immune cells. Materials-based vaccination strategies can augment the immune response by improving innate immune cell activation, creating local inflammatory niches, targeting lymph node delivery and controlling the time frame of vaccine delivery, with the goal of inducing enhanced memory immunity to protect against future infections. In this Review, we highlight the biological mechanisms underlying strong humoral and cell-mediated immune responses and explore materials design strategies to manipulate and control these mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Designing spatial and temporal control of vaccine responses

et al. 2021

View full text Add to dashboard Cite

show abstract

“…When comparing NPs, there are several physiochemical properties that can vary from platform to platform, but also influence how the NPs interact with APCs and other immune cells ( 22 ). Of the physiochemical characterization of NPs for vaccines, surface charge, particle size, loading capacity of the particles, and drug release are the most commonly reported.…”

Section: Characterization Of Nanoparticlesmentioning

confidence: 99%

“…An important control in the evaluation of innate activity is a vehicle-only control since high production of cytokines can indicate endotoxin contamination. Endotoxin contamination cannot be removed with filtering, but can be easily determined by absorbance with the limulus amebocyte lysate (LAL) test that can quantitatively measure the amount of endotoxin in a sample ( 22 ). Uptake studies by APCs are also an important in vitro assay that is best performed using fluorescent dyes (e.g., fluorescence activated cell sorting/scanning (FACS)) and confocal microscopy ( 25 , 26 ).…”

Section: Characterization Of Nanoparticlesmentioning

confidence: 99%

Nano/microparticle Formulations for Universal Influenza Vaccines

Hendy

Amouzougan

Young

et al. 2022

AAPS J

Self Cite

View full text Add to dashboard Cite

Influenza affects millions of people worldwide and can result in severe sickness and even death. The best method of prevention is vaccination; however, the seasonal influenza vaccine often suffers from low efficacy and requires yearly vaccination due to changes in strain and viral mutations. More conserved universal influenza antigens like M2 ectodomain (M2e) and the stalk region of hemagglutinin (HA stalk) have been used clinically but often suffer from low antigenicity. To increase antigenicity, universal antigens have been formulated using nano/microparticles as vaccine carriers against influenza. Utilizing polymers, liposomes, metal, and protein-based particles, indicators of immunity and protection in mouse, pig, ferrets, and chicken models of influenza have been shown. In this review, seasonal and universal influenza vaccine formulations comprised of these materials including their physiochemical properties, fabrication, characterization, and biologic responses in vivo are highlighted. The review is concluded with future perspectives for nano/microparticles as carrier systems and other considerations within the universal influenza vaccine delivery landscape. Graphical Abstract

show abstract

“…Nanoplatform infrastructures provide improved efficacy in relation to conventional vaccines and marketable tools to fight infectious diseases involving negligible financial risk. Although not the panacea, the future of vaccine research and development may pass through nanoplatform-based approaches for many pathogens [ 75 , 93 , 94 ]. NPs have different roles in vaccinology mainly as adjuvants, carriers, and platforms.…”

Section: Nanoplatforms: Modern Approaches For Producing Real Anti-pathogen Vaccinesmentioning

confidence: 99%

Nanovaccines against Animal Pathogens: The Latest Findings

et al. 2021

View full text Add to dashboard Cite

Nowadays, safe and efficacious vaccines represent powerful and cost-effective tools for global health and economic growth. In the veterinary field, these are undoubtedly key tools for improving productivity and fighting zoonoses. However, cases of persistent infections, rapidly evolving pathogens having high variability or emerging/re-emerging pathogens for which no effective vaccines have been developed point out the continuing need for new vaccine alternatives to control outbreaks. Most licensed vaccines have been successfully used for many years now; however, they have intrinsic limitations, such as variable efficacy, adverse effects, and some shortcomings. More effective adjuvants and novel delivery systems may foster real vaccine effectiveness and timely implementation. Emerging vaccine technologies involving nanoparticles such as self-assembling proteins, virus-like particles, liposomes, virosomes, and polymeric nanoparticles offer novel, safe, and high-potential approaches to address many vaccine development-related challenges. Nanotechnology is accelerating the evolution of vaccines because nanomaterials having encapsulation ability and very advantageous properties due to their size and surface area serve as effective vehicles for antigen delivery and immunostimulatory agents. This review discusses the requirements for an effective, broad-coverage-elicited immune response, the main nanoplatforms for producing it, and the latest nanovaccine applications for fighting animal pathogens.

show abstract

Considerations for Size, Surface Charge, Polymer Degradation, Co‐Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases

Cited by 47 publications

References 166 publications

Designing spatial and temporal control of vaccine responses

Designing spatial and temporal control of vaccine responses

Nano/microparticle Formulations for Universal Influenza Vaccines

Nanovaccines against Animal Pathogens: The Latest Findings

Contact Info

Product

Resources

About